Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hi-ClearanceROCO:1788 81 Days Payable is 69.21 as of Jun. 2026, which is 21% below its 10-year median of 87.89. GuruFocus rates ROCO:1788 with a GF Score™ of 81/100 and a GF Value™ of NT$146.08 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Hi-Clearance ranks better than 50.82% on this metric.
The historical rank and industry rank for Hi-Clearance's Days Payable or its related term are showing as below:
ROCO:1788'
s Days Payable Range Over the Past 10 Years
Min: 68.17 Med: 87.89 Max: 99.29
Current: 70.78
During the past 13 years, Hi-Clearance's highest Days Payable was 99.29. The lowest was 68.17. And the median was 87.89.
ROCO:1788's Days Payable is ranked better than 50.82% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.6
vs ROCO:1788: 70.78
Hi-Clearance's Days Payable
increased
from Jun. 2025 (68.08) to Jun. 2026 (69.21).
It may suggest that Hi-Clearancedelayed paying its suppliers.
The historical data trend for Hi-Clearance's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1788 vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Hi-Clearance's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hi-Clearance Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hi-Clearance's Days Payable distribution charts can be found below:
* The bar in red indicates where Hi-Clearance's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Hi-Clearance's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hi-Clearance (ROCO:1788) has a Days Payable of 69.21 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hi-Clearance and its competitors. This is 21% below median its historical median of 87.89. Over the past decade, Hi-Clearance's Days Payable has ranged from 68.17 to 99.29. According to the industry distribution chart, Hi-Clearance ranks #391 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 49.2%.
Is Hi-Clearance's Days Payable too high?
Hi-Clearance's current Days Payable of 69.21 is 21% below median its 10-year median of 87.89. Over the past 10 years, this metric has ranged from a low of 68.17 to a high of 99.29. The Medical Devices & Instruments industry median Days Payable is 68.60. Hi-Clearance's value of 69.21 is 0.9% above this industry median. Based on the distribution chart, Hi-Clearance ranks #391 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Hi-Clearance has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hi-Clearance's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Hi-Clearance ranks #391 out of 795 companies for Days Payable. This puts Hi-Clearance in the upper half of its industry. The industry median Days Payable is 68.60. Hi-Clearance's value of 69.21 is 0.9% above this benchmark. Historically, Hi-Clearance's own Days Payable has ranged from 68.17 to 99.29 over the past decade. While the company's 10-year median is 87.89 vs. the industry median of 68.60, Hi-Clearance has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.60, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hi-Clearance's current Days Payable of 69.21 is 0.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hi-Clearance and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hi-Clearance's current Days Payable is 69.21, which is 21% below median its own 10-year median of 87.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hi-Clearance stock overvalued right now?
Based on GuruFocus' analysis, Hi-Clearance (ROCO:1788) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$146.08, compared to a current price of NT$128.00 — trading 12.4% below its estimated fair value. The current Days Payable is 69.21, which is 21% below median its 10-year median of 87.89 and 0.9% above the Medical Devices & Instruments industry median of 68.60. Hi-Clearance's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hi-Clearance (ROCO:1788), the current Days Payable is 69.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hi-Clearance (ROCO:1788) Overvalued in 2026?
Based on GuruFocus' analysis, Hi-Clearance stock appears to be undervalued.
The current stock price of NT$128.00 is trading 12.4% below its estimated GF Value™ of NT$146.08.
GuruFocus considers Hi-Clearance to be Modestly Undervalued.
Key valuation signals for ROCO:1788:
Days Payable: 69.21 (21% below median its 10-year median of 87.89)
GF Value™: NT$146.08 vs. price of NT$128.00 (12.4% below fair value)
Industry Position: 0.9% above the Medical Devices & Instruments median (#391 of 795)
No single metric tells the full story. See the ROCO:1788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hi-Clearance Inc primary business activities involve trading medical equipment, biochemical reagents, and Western medicine. It has two segments Hemodialysis Division responsible for the procurement and distribution of a wide range of blood dialysis-related consumables, which are sold to hospitals, clinics, and distributors; and Other business segments mainly involved in selling dental materials and other products. The company generates majority of revenue from Hemodialysis Division. Its products are Single Patient Dialysis System TORAY, TORAYLIGHT Hollow Fiber Dialyzer, FILTRYZER TORAY, TORAY ETRF.
81GF Score
Get the complete analysis for ROCO:1788
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1788 has been successfully added to your 
